Pfizer CFO exits; GSK wins FDA nod for oral UTI drug; Apellis trial paused; plus Mersana ADC dropped, TORL ADC data, Corcept resubmission, Verastem pancreatic update, Legend offering, COUR Series B and two program cuts, cAMPfield $180M debut and LabGenius-LG Chem AI pact.
Plus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer CFO to step down; Denali sells a regulatory fast-pass
Lilly's Ajax acquisition may have been worth it
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Another big deal, another sign biotech M&A is back
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
FDA appears open to Moderna's flu vaccine ahead of adcomm
